Comparison of adverse reactions of spiramycin versus pyrimethamine/sulfadiazine treatment of toxoplasmosis in pregnancy: is spiramycin really the drug of choice for unproven infection of the fetus?

Figures & data

Figure 1. Complications of toxoplasmosis treatment in pregnant women. Frequency of the individual complications is listed as number of patients followed by percentage of total in A) pregnant women treated by spiramycin (n = 77) and B) pregnant women treated by pyrimethamine/sulfadiazine (n = 35).

Table 1. Complications of anti-toxoplasma therapy of pregnant women.

adverse effect	spiramycin (n = 77)	pyrimethamine with sulfadiazine (n = 35)	p-value
no complications	47 (61,1%)	24 (68,6%)	.53
paresthesias	15 (19,5%)	0 (0%)	.003
toxoalergy	7 (9,1 %)	3 (8,6%)	1.00
GIT disorders	6 (7,8%)	5 (14,3%)	.32
vaginal dyscomfort	1 (1,3%)	0 (0%)	1.00
lab. abnormalities	1 (1,3%)	3 (8,6%)	.09
total adverse effect	30 (38,9 %)	11 (31,4%)	.53

*Categorical variables were compared using Fisher’s exact test. Statistically significant results (p ≤ .05) are marked in bold.

Data availability statement

Data are available on request due to ethical restrictions.